Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
This NIH R21 award supports early-stage, high-risk exploratory research into the cellular, molecular, and circuit biology of risk factors for complex brain disorders, with no clinical trials allowe…
- Deadline
- Sep 7, 2026
- Posted
- Nov 18, 2024
- Award amount
- Amount not specified
- Focus areas
- Health
Don’t miss this deadline
We’ll email you before Sep 7, 2026 so you have time to apply.
In plain English
This NIH R21 award supports early-stage, high-risk exploratory research into the cellular, molecular, and circuit biology of risk factors for complex brain disorders, with no clinical trials allowed. It is aimed at research institutions and investigators, with a broad list of eligible U.S. organization types. Award amounts are not specified here. Applications are submitted through eligible organizations rather than by individuals.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this grant
This Notice of Funding Opportunity (NOFO) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this NOFO, the term complex can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to model disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present NOFO (R21 activity code) can be used for applications to develop early stage, high-risk, exploratory approaches or establish proof-of-concept where there is little or no preliminary data. Applicants proposing to develop lines of inquiry where feasibility or proof of concept has been established should apply to the companion R01 NOFO (PAR-xx-xxx).
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Health — soonest deadline first.
Alcohol Health Services Research (R34 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due in 17 days
Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due in 17 days
Alcohol Health Services Research (R01 Clinical Trial Optional)
National Institutes of Health · Up to $500K · Due in 17 days
Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)
National Institutes of Health · Amount varies · Due in 17 days
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due in 17 days
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due in 17 days
Also listed under National Institutes of Health and Health Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.